Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
In this case study, you will hear Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, describing how new, highly sensitive, and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment to save the lives of transplanted.
In this case study, you will hear Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, describing how new, highly sensitive, and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment to save the lives of transplanted.
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More